ArticleBMJ case reports2026
Orbital and skull metastases as the initial presentation of lung adenocarcinoma harbouring a MET exon 14 skipping mutation.
Article in BMJ case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A man in his 70s presented with right ocular pain, visual disturbance, forehead swelling and left iliac pain. Diagnostic imaging revealed a large right orbital-frontal mass with skull involvement, a cavitary lesion in the right upper lobe and a left iliac lesion. Histological and molecular analyses confirmed lung adenocarcinoma with a MET exon 14 skipping mutation. Initial management focused on symptom control via palliative radiotherapy to the orbital and iliac lesions which achieved rapid relief. Following molecular confirmation, tepotinib-a selective MET tyrosine kinase inhibitor-was initiated. This resulted in clinical stability and a slight radiographic reduction of the primary lung lesion. This case highlights an atypical clinical manifestation of orbital metastasis in MET-mutated non-small-cell lung cancer. It underscores the clinical necessity of prompt tissue diagnosis and molecular profiling in patients presenting with atypical metastatic sites to facilitate the timely initiation of targeted systemic therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.